Skip to main content
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. — Investor Relations & Filings

Ticker · XBIO ISIN · US9840155033 LEI · 5493002WV0KYX8JXAH52 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2026-05-13 Report Publication Anno…
Country US United States of America
Listing US XBIO

About Xenetic Biosciences, Inc.

https://www.xeneticbio.com/

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing proprietary technology platforms for immune-oncology. The company's development pipeline is centered on its XCART platform, a personalized CAR T-cell therapy technology, and its DNase-based oncology platform. The DNase platform is designed to improve cancer therapies by targeting Neutrophil Extracellular Traps (NETs), which are implicated in cancer progression, metastasis, and resistance to treatments. Xenetic's research aims to address multiple high-value, difficult-to-treat cancer indications, including pancreatic cancer and other solid tumors.

Recent filings

Filing Released Lang Actions
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
Report Publication Announcement Classification · 82% confidence The document is a Current Report on Form 8-K that does not itself present the financial results but rather announces that a press release with the three-month financial results is furnished as Exhibit 99.1. It does not contain the actual earnings figures and serves to notify investors that the earnings release has been issued and is attached, fitting the definition of a Report Publication Announcement (RPA).
2026-05-13 English
10-K/A - Xenetic Biosciences, Inc. (0001534525) (Filer)
Annual Report
2026-04-24 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the adjournment of the company's 2025 Annual Meeting of Stockholders due to lack of quorum and plans to reconvene. There is no financial data, no detailed report, or presentation included. The document is a regulatory announcement about a corporate event rather than a full report or detailed filing. Given the nature and length (3836 characters), it is not a full Annual Report or Interim Report. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-01-09 English
Director's Dealing 2026
Director's Dealing
2026-01-05 English
Director's Dealing 2026
Director's Dealing
2026-01-05 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.